

Allison C Rosenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6661628/publications.pdf>

Version: 2024-02-01

62
papers

626
citations

840776

11
h-index

713466

21
g-index

62
all docs

62
docs citations

62
times ranked

956
citing authors

#	ARTICLE	IF	CITATIONS
1	High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. <i>Blood Reviews</i> , 2017, 31, 37-42.	5.7	180
2	Exercise and the immune system: taking steps to improve responses to cancer immunotherapy. , 2021, 9, e001872.		49
3	Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1265-1276.	1.8	31
4	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. <i>Radiotherapy and Oncology</i> , 2022, 166, 171-179.	0.6	27
5	Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. <i>Leukemia and Lymphoma</i> , 2021, 62, 2554-2555.	1.3	24
6	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (<sc>MLN</sc>8237) and Bortezomib in Relapsed Multiple Myeloma. <i>British Journal of Haematology</i> , 2016, 174, 323-325.	2.5	22
7	Identifying and Meeting the Needs of Adolescents and Young Adults with Cancer. <i>Current Oncology Reports</i> , 2021, 23, 17.	4.0	21
8	Extramedullary Cardiac Multiple Myeloma—A Case Report and Contemporary Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 246-252.	0.4	16
9	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	4.1	16
10	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR&CD) for untreated low&grade non&Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	4.1	15
11	Genomics of aggressive B-cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 69-74.	2.5	15
12	Incorporation of digital gene expression profiling for cell-of-origin determination (Lymph2Cx testing) into the routine work-up of diffuse large B cell lymphoma. <i>Journal of Hematopathology</i> , 2019, 12, 3-10.	0.4	14
13	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	1.7	13
14	Assessment of fixed&duration therapies for treatment&na&ve <sc>Waldenstr&om</sc> macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	4.1	12
15	Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 207-216.	2.3	10
16	Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta&analysis. <i>American Journal of Hematology</i> , 2018, 93, 1220-1226.	4.1	9
17	A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 810-810.	1.4	9
18	Primary Effusion Lymphoma: A Clinicopathologic Perspective. <i>Cancers</i> , 2022, 14, 722.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. <i>Respiratory Medicine Case Reports</i> , 2018, 25, 129-132.	0.4	8
20	Classical Hodgkin lymphoma masquerading as chronic recurrent multifocal osteomyelitis: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 45.	0.8	7
21	Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma. <i>Journal of Hematopathology</i> , 2020, 13, 231-238.	0.4	7
22	Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with SÅ©zary syndrome. <i>JAAD Case Reports</i> , 2021, 9, 24-27.	0.8	7
23	Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: Diagnosis and management. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1167-1169.	1.2	7
24	The association of health behaviors with quality of life in lymphoma survivors. <i>Leukemia and Lymphoma</i> , 2021, 62, 271-280.	1.3	6
25	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>Advances in Radiation Oncology</i> , 2021, 6, 100714.	1.2	6
26	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	6.2	6
27	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2128-2134.	1.3	5
28	Quality of Life and Survivorship in Lymphoma. <i>Current Oncology Reports</i> , 2022, 24, 1113-1120.	4.0	5
29	Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3581-3583.	1.3	4
30	Syngotropic and folliculotropic mycosis fungoides with mycosis fungoides-associated vasculopathic ulcers. <i>JAAD Case Reports</i> , 2019, 5, 231-233.	0.8	4
31	The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis. <i>Current Problems in Diagnostic Radiology</i> , 2021, 50, 443-449.	1.4	4
32	Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 969-971.	1.2	4
33	Phase 1 Dose-Finding Study Investigating CA-4948, an IRAK4 Kinase Inhibitor, in Patients with R/R NHL: Report of Initial Efficacy and Updated Safety Information. <i>Blood</i> , 2019, 134, 5327-5327.	1.4	4
34	The Brief Case: The Unexpected Souvenir. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	3
35	Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin. <i>JAAD Case Reports</i> , 2020, 6, 19-22.	0.8	3
36	Glucocorticoid-Induced Hypermetabolism in White Adipose Tissue in Cushing Syndrome. <i>Journal of Nuclear Medicine Technology</i> , 2020, 48, 285-286.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma. Current Treatment Options in Oncology, 2021, 22, 64.	3.0	3
38	Primary cutaneous epidermotropic marginal zone B-cell lymphoma treated with total skin electron beam therapy. JAAD Case Reports, 2021, 15, 15-18.	0.8	3
39	How to Sequence Therapies in Mycosis Fungoides. Current Treatment Options in Oncology, 2021, 22, 101.	3.0	3
40	Association of Health Behaviors and Quality of Life in Lymphoma Survivors. Blood, 2018, 132, 4838-4838.	1.4	3
41	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. Blood, 2021, 138, 2527-2527.	1.4	3
42	Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas. Current Treatment Options in Oncology, 2022, 23, 89-98.	3.0	3
43	The blue man: a novel cutaneous manifestation of systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 156-159.	3.0	2
44	Pitfall of ¹⁸ F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. Journal of Nuclear Medicine Technology, 2018, 46, 396-397.	0.8	2
45	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e89-e95.	0.4	2
46	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
47	Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination. Blood, 2021, 138, 4218-4218.	1.4	2
48	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. Blood, 2021, 138, 1750-1750.	1.4	2
49	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. Blood, 2021, 138, 1373-1373.	1.4	2
50	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e815-e825.	0.4	2
51	Closing the Brief Case: The Unexpected Souvenir. Journal of Clinical Microbiology, 2018, 56, .	3.9	1
52	Breast implant-associated anaplastic large cell lymphoma and the obligation of insurance providers. Breast Journal, 2020, 26, 2110-2111.	1.0	1
53	Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. Blood, 2018, 132, 5384-5384.	1.4	1
54	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). Blood, 2019, 134, 5343-5343.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	1.4	1
56	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. <i>Blood</i> , 2021, 138, 3517-3517.	1.4	1
57	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2495-2495.	1.4	1
58	Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report. , 2021, 3, e0472.		0
59	Clinical Features and Cell of Origin Subtyping Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 2977-2977.	1.4	0
60	Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018, 132, 2847-2847.	1.4	0
61	Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance. <i>Blood</i> , 2019, 134, 2774-2774.	1.4	0
62	Transformation of Follicular Lymphoma into Primary Mediastinal B-Cell Lymphoma-like Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4479-4479.	1.4	0